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Abstract 
To maximize the risk benefit ratio of blood pressure control in people 
with chronic kidney diseases (CKD), a number of guidelines provide 
recommendations on optimal BP targets in CKD. This review examines 
these guidelines, their supporting evidence base and generalizability and 
limitations of current standards of care. Over the years, the BP targets 
are liberalized. They now focus on the usual BP target of <140/90 
mmHg.  In the elderly, where guidelines call for a target of <150/90 
mmHg in the general population, the recommendations provide room 
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for the clinician to tailor therapy.  Among those with albuminuria of 
>300 mg/g creatinine low quality evidence suggests targeting BP to 
<130/90 mmHg.  Individualization of BP lowering is key based on 
comorbid conditions, response to treatment and level of kidney 
function.  Consideration of out of clinic BP monitoring either 
implemented by home BP recordings or ambulatory BP measurements 
may enhance BP control.  
 
Introduction 
 
Hypertension is a major public health problem affecting almost a third of 
US population [1]. Worldwide, high blood pressure is one of the 5 
leading risk factors for global burden of disease. More than 60% patients 
of CKD have hypertension [1]. Control of blood pressure in CKD subjects 
is an important strategy to reduce the burden of cardiovascular disease, 
the progression of CKD, development of ESRD and mortality. The 
Prospective Studies Collaboration showed an increase in vascular risk in 
population starting with pressures as low as 115/75 and the risk doubled 
with each 20/10 mm Hg rise in BP [2]. Although the data in CKD are less 
clear, the relative magnitude of cardiovascular protection in CKD is 
believed to be similar.  Furthermore, an independent association exists 
between albuminuria and both CVD and progression of CKD. 
Albuminuria is known to act as a risk multiplier for CVD in CKD patients 
[3]. Blood pressure reduction has been shown to be associated with 
reduction in albuminuria and progression of CKD. 
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In order to maximize the risk benefit ratio of blood pressure control in 
CKD subjects, a number of guidelines provide recommendations on 
optimal BP targets in CKD. This review examines these guidelines, their 
supporting evidence base and generalizability and limitations of current 
standards of care. The scope of this review is restricted to non dialysis-
dependent CKD; kidney transplant recipients are also excluded. 
 
 
Key Studies exploring the BP target in CKD 
 
Over the last few years many guidelines on BP control in CKD and 
accompanying commentaries have been published. With respect to high 
quality evidence, three prospective randomized multicenter trials and 
three meta-analyses have specifically examined how far BP should be 
lowered among patients with CKD. These trials were the Modification of 
Diet in Renal Disease (MDRD) study [4], the African American Study of 
Kidney Disease (AASK) study [5] and the BP control for Renoprotection in 
Patients with Nondiabetic Chronic Renal Disease (REIN-2) trial [6].  Table 
1 provides a summary of these studies. 
 
 
Modification of Diet in Renal Disease Study 
 
The MDRD study was the first prospective randomized controlled trial 
examining the effect of different BP targets on renal outcomes [4].  The 
study had a 2 x 2 factorial design.  The two factors examined were 
dietary protein restriction and BP control; each factor had two levels.  
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Furthermore, the baseline level of glomerular filtration rate (GFR) was 
used as a stratification variable. Thus, study 1 used a higher level of GFR 
and study 2 a lower level.  Accordingly, in study 1, 585 patients with 
GFRs of 25–55ml/min/1.73m2 of body surface area were randomly 
assigned to a usual- protein diet or a low-protein diet and to a usual or a 
low BP group. Within each factor, mean arterial pressure was targeted 
to be <92 mmHg (low BP group) or <107 mmHg (usual BP group).   In 
study 2, 255 patients with GFRs of 13–24 ml/ min/1.73m2 were 
randomly assigned to the low-protein diet or a very-low-protein diet 
with a keto acid-amino acid supplement, and a usual or a low BP group.  
Renal function in this trial was measured using 125I iothalamate 
clearance. It is to be noted that diabetic nephropathy was the underlying 
renal disease in only 3% of patients.  Furthermore, BP target was not 
systolic or diastolic BP values and the mean arterial pressure of lower 
and usual BP arm would roughly correspond to BP of 125/75 mmHg and 
140/90 mmHg respectively. The projected mean decline in the GFR at 3 
years did not differ significantly between the BP groups. As compared 
with the usual BP group, the low BP group had a more rapid decline in 
the GFR during the first 4 months after randomization and a slower 
decline thereafter.  
 
However, in post hoc analysis a significant interaction between BP target 
and baseline proteinuria on renal function decline was noted [7].  Thus, 
low BP treatment goal showing greater benefit in those with proteinuria 
exceeding 3g per day at baseline, moderate in those with proteinuria 
between 1 and 3g per day, and no benefit in those with proteinuria of 
less than 1g per day [7]. These post hoc analysis findings led to the 
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recommendation by the K-DOQI and the Joint National Committee on 
Prevention, Detection, Evaluation and Treatment of High Blood Pressure 
(JNC 6) of a BP goal of less than 125/75mmHg among CKD patients with 
> 1 g/day proteinuria which were later taken off from the more recent 
guidelines [8] due to concerns about the strength of the data to justify a 
recommendation.  
Post hoc analysis suggested that a lower BP target might be more 
effective in preventing renal disease progression in black versus white 
patients [9] and that blacks have higher nocturnal BP and may benefit 
from greater nocturnal BP lowering [10].   Furthermore, a follow up 
analysis of the MDRD cohort for 7 years revealed fewer ESRD or 
combined ESRD and death events in the more aggressive BP lowering 
group [11].  The post hoc or observational nature of these data does not 
allow firm conclusions regarding their applicability to the care of 
patients with hypertension and CKD. 
 
The use of mean arterial pressure to target BP therapy has been 
questioned. Mean arterial pressure is not the measure of BP control 
used in practice or a benchmark in standard guidelines. Further, the very 
nature of its derivation (diastolic pressure + one third of pulse pressure) 
allows for a wide range of systolic blood pressures for any given value of 
mean arterial pressure. As illustrated by Lewis, the low-mean arterial 
pressure group had a wide range of systolic pressure, approximately 98 
to 154 mmHg. Achieving systolic blood pressure in this range is a very 
different intervention than targeting all patients’ BP to <130 mmHg 
systolic.  
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Blood pressure control for Renoprotection In Nondiabetic 
Chronic Renal Disease (REIN-2)  
 
The REIN-2 trial assessed the effect of intensified versus conventional BP 
control on progression to ESRD [6]. Participants had non-diabetic 
proteinuric nephropathies receiving background treatment with the ACE 
inhibitor ramipril (2.5–5 mg/day). They were randomly assigned to 
either conventional (diastolic <90mmHg; n=169) or intensified 
(systolic/diastolic <130/80mmHg; n=169) BP control. To achieve the 
intensified BP level, patients received add-on therapy with the 
dihydropyridine calcium-channel blocker felodipine (5–10 mg/day). 
Although the primary outcome measure was time to ESRD over 36 
months’ follow-up the study was terminated early for futility with a 
conclusion that among patients with nondiabetic proteinuric 
nephropathies receiving background ACE- inhibitor therapy, no 
additional benefit from further BP reduction by felodipine could be 
shown. In effect, over a median follow-up of 19 months, 38/167 (23%) 
and 34/168 (20%) subjects in intervention and control arm progressed to 
ESRD [hazard ratio 1.00 (95% CI 0.61–1.64); P=0.99].  
 
African American Study of Kidney Disease (AASK) 
 
The AASK compared the effects of two levels of BP control and three 
antihypertensive drug classes on GFR decline in hypertension in a 3 x 2 
factorial trial design [12]. The 3 factors were the initial open-label drug 
therapies: the ACE-inhibitor ramipril, the beta-blocker metoprolol, or the 
dihydropyridine calcium- channel blocker amlodipine.  Within each 
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factor, participants were randomly assigned to one of two mean arterial 
pressure goals as in the MDRD study. Importantly, subjects with 
proteinuria of greater than 2.5 g/g creatinine and type 1 and type 2 
diabetes were excluded. Three primary treatment comparisons were 
specified: lower versus usual BP goal; ramipril versus metoprolol; and 
amlodipine versus metoprolol.  
Achieved BP averaged (SD) 128/78 (12/8) mmHg in the lower BP group 
and 141/85 (12/7) mmHg in the usual BP group. The mean (SE) GFR 
slope from baseline through 4 years did not differ significantly between 
the lower BP group and the usual BP group. The rates of the clinical 
composite outcome (table 1) [risk reduction for lower BP group=2%; 
95% confidence interval (CI) -22 to +21%; P=0.85) were no different. A 
sub-analysis did not find a difference in outcome between two BP 
targets in subjects with urinary protein > 0.22 per gm creatinine. Thus, 
no additional benefit of slowing progression of hypertensive 
nephrosclerosis was observed with the lower BP goal. A subsequent 
study on the observation cohort reported that the lower BP group with 
proteinuria > 0.22 per gm creatinine experienced a lower (hazard ratio 
0.73, p=0.01) composite endpoint occurrence [13].  
 
None of these three landmark randomized controlled trials revealed any 
significant improvement in cardiovascular disease outcomes in relation 
to intensive vs. usual BP control. The AASK investigators acknowledged 
that the trial was not powered to detect differences in the rate of 
myocardial infarction, stroke, or death.  
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In contrast to above, a meta-analysis suggests that BP control reduces 
CVD outcomes in CKD. A meta-analysis of RCTs by the Blood Pressure 
Lowering Treatment Trialists’ Collaboration that comprised 26 trials 
(152,290 participants), had 30,295 individuals with eGFR <60 
mL/min/1.73m2 [14]. The results  showed that compared with placebo, 
blood pressure lowering regimens reduced the risk of major 
cardiovascular events by about 17% per 5 mm Hg reduction in systolic 
blood pressure in individuals with (hazard ratio 0.83, 95% CI 0.76 to 
0.90) and without reduced eGFR (0.83, CI 0.79 to 0.88). The report did 
not identify any clear benefit for more intensive compared with less 
intensive blood pressure lowering regimens in people with CKD, 
although there was only limited power for this analysis.  
 
Similarly, the absence of diabetics from key studies is a major limitation. 
Diabetes comprises the largest segment of CKD but AASK and REIN 2 
excluded these people and MDRD had just 3%. Therefore, there are no 
adequately powered studies on diabetic CKD targeting intensive vs 
conventional BP control.  
Meta analyses of BP targets in CKD 
The subject of intensive blood pressure lowering in CKD has been a part 
of three meta-analyses as well. Table 2 summarizes the key aspects of 
these meta-analyses 
 
Upadhyay et al included studies after 2001 only and thus had the three 
key trials and associated sub-group, post hoc analyses and observation 
cohort data studies included for analysis [15]. While the primary result 
was negative, lower-quality evidence suggested that a lower BP target 
 9 
might be beneficial in subgroups with proteinuria greater than 300 to 
1000 mg/d. It was also noted that participants in the low target groups 
needed more antihypertensive medications and had a slightly higher 
rate of adverse events.  
 
In another meta-analysis that was limited to patients with CKD but 
included several observational follow up cohorts such as from the AASK 
study [13] Lv et al [16] showed a benefit of intensive blood pressure 
lowering and more so among patients with proteinuria. There was no 
clear benefit of aggressive BP lowering on the risk of cardiovascular 
events or death.  However, given that the observational cohorts were 
included in the analyses, a cause and effect relationship is difficult to 
establish [16]. 
 
Evolution of BP targets in CKD 
Among people with hypertension with little cardiovascular disease at 
baseline, meta-analyses of randomized trials indicate that patients who 
achieve lower BP have fewer cardiovascular events; no J curve was 
evident [2].  A J-curve is however reported for achieved BP in CKD with 
an observed increased risk for stroke, cardiovascular morbidity and 
mortality [17-19].  No such J-curve is noted for renal protection [20].  
Over time, it has become increasingly clear that a distinction needs to be 
made between achieved BP and targeted BP.  Achieved BP may reflect 
severity of disease, coexisting illness, adherence to medications and 
lifestyle modifications, factors beyond what may be studied in a 
randomized trial.  Target BP can only be examined in a randomized trial 
and results of these trials can inform practice.   
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Perhaps this is best illustrated by an analysis of the AASK study [21].  
Intention-to-treat analyses showed no evidence of a BP effect on either 
the rate of decline in glomerular filtration rate or the clinical composite 
outcome. In contrast, the achieved BP analyses showed that each 10-
mm Hg increment in mean follow-up achieved mean arterial pressure 
was associated with a 0.35 mL/min per 1.73 m2 (p=0.01) faster mean 
glomerular filtration rate decline and a 17% (p=0.006) increased risk of 
the clinical composite outcome. Even within a randomized trial, analyses 
based on achieved BP lead to markedly different inferences than 
traditional intention-to-treat analyses. 
 
Current guidelines on blood pressure targets in CKD 
 
Over time, the recommended BP targets in CKD have risen.  This is 
because the more recent guidelines have come to rely more on RCTs 
with primary outcomes as BP targets unlike the earlier guidelines that 
based guidance on observational studies, post hoc analyses and sub 
group analyses of RCTs. The latter usually provide a lower quality of 
evidence. For example, observational studies can only evaluate the 
achieved BP and associate them with outcomes.  They fall short in 
informing on what the BP targets should be. Eventually, the randomized 
controlled trials targeting BP values are able to inform clinical practice.  
 
We will discuss the newest guidelines by KDIGO in some detail.  The 
KDIGO guidelines use the Grades of Recommendation Assessment, 
Development, and Evaluation (GRADE) methodology for grading the 
quality of evidence and strength of recommendations.  Broadly 
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speaking, each guideline has both strength of recommendation and 
quality of evidence to support it. 
1.  The strength of recommendation is graded as Level 1, Level 2, or 
Not Graded. Level 1 guideline is a recommendation, whereas level 
2 is a suggestion.  Level 1 guidelines have several implications for 
clinicians, policy makers, and patients.  For clinicians, the 
implication of Level 1 guideline is that most patients should 
receive the recommended course of action.  For policy makers this 
level of evidence can be evaluated to become a performance 
measure. For patients, most individuals would want the 
recommended course of action and only a small proportion would 
not.  
2. The quality of evidence to support a guideline is rated.  The 
quality is rated as A if high, B if moderate, C if low, and D if very 
low quality of evidence is present to support the guideline.  
No guidelines received the venerated rating of IA.  In fact, there is no 
statement that is supported by high quality evidence (grade A).   
 
The KDIGO guidelines recommend with BP goal of ≤140/90 mmHg for 
anyone with no albuminuria whether they have diabetes mellitus or not 
and give it its best strength of recommendation and highest quality of 
evidence (Level 1B)  
 
Goal BP of <130/80 mmHg was a recommendation for all people with 
CKD in the earlier guidelines.  For people with albuminuria >30 mg/24h, 
now the goal BP of ≤130/80 mmHg for diabetic CKD receives Grade 2D. 
Among those with non-diabetic CKD, goal BP of ≤130/80 gets a grade of 
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2D if albuminuria is 30-300 mg/24h and 2C if albuminuria is >300 
mg/24h. In other words, the goal BP is a suggestion based on low to very 
low quality evidence. These grades are appropriate because randomized 
trial data are lacking to support these recommendations. 
 
Specifically for patients with diabetes and CKD, RCTs that examine the 
BP to which treatment should be targeted to are conspicuously lacking. 
The three key trials mentioned earlier either did not have diabetics or 
had only a small proportion of them in the study.  
 
Is there an evidence-based lower limit for BP reduction? The expert 
group convened by KDIGO concluded, “we are left without a lowest BP 
target”.  Should a reduction in albuminuria be a target for treatment 
with agents that modify BP? There have been no RCTs assessing hard 
renal or CV outcomes, in which patients have been randomized to 
different targets of urinary albumin excretion irrespective of BP so at 
present the answer is no.  
 
BP and CKD in the elderly 
 
With the demographic shift increasing the proportion of elderly subjects 
in population, this group is rapidly increasing in size.  The term ‘elderly’ 
is used for persons >65 years of age whereas ‘very elderly’ is reserved 
for persons >80 years of age. Hypertension management in this group of 
patients is challenging because of vascular disease, autonomic 
dysfunction, difficult to control systolic hypertension, polypharmacy and 
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drug interactions, cognitive effects of antihypertensive therapy, post-
prandial hypotension, and orthostatic hypotension.  
A Cochrane review of 15 trials with 24,055 participants aged 60 years or 
more who had moderate to severe hypertension demonstrated relative 
risk reduction in all-cause mortality by 10%, and cardiovascular 
morbidity and cardiovascular mortality by 28% [22].   In the very elderly, 
reduction in cardiovascular morbidity and mortality was 25%, but no 
effect on all-cause mortality was seen. The JNC 8 recommends BP target 
<150/90 mmHg in those older than 60 years [23] 
Given that there are limited randomized trial evidence in this population 
with CKD, the KDIGO guidelines for elderly suggest to “tailor BP 
treatment regimens in elderly patients with CKD by carefully considering 
age, co-morbidities and other therapies, with gradual escalation of 
treatment and close attention to adverse events related to BP 
treatment, including electrolyte disorders, acute deterioration in kidney 
function, orthostatic hypotension and drug side effects.” [24]   This 
guideline was not graded. 
 
Individualizing antihypertensive therapy 
Given the complexity and heterogeneity of CKD, the lack of evidence in 
many important subgroups of patients, “one size fits all” may not work 
for all.  Even while being treated with antihypertensive drugs, the 
importance of lifestyle advice requires emphasis.  These include 
guidance of dietary sodium restriction, weight loss, regular physical 
activity, moderation of alcohol intake, and tobacco avoidance.  Even 
though not tested in CKD, BP control through these life-style 
modifications may provide benefits over the long term.   
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Guidelines propose that clinicians individualize therapy.  For example, 
the KDIGO guidelines state: individualize BP targets and agents 
according to age, co-existent cardiovascular disease and other co-
morbidities, risk of progression of CKD, presence or absence of 
retinopathy (in CKD patients with diabetes) and tolerance of treatment. 
They exhort us to inquire about postural dizziness and check for postural 
hypotension regularly when treating CKD patients with BP-lowering 
drugs. Neither of these guidelines are graded, but form the basis of good 
clinical practice.   
 
Evaluation of BP can be challenging. The clinic BP has been the 
benchmark for most studies; the entities of white coat hypertension and 
“masked hypertension” require special attention. Whereas, 20-25% of 
the patients may have a white coat effect, it is now estimated that 25% 
of people with CKD who have seemingly normal BP in the clinic have 
masked hypertension. Emerging data supports the notion that masked 
hypertension is associated with increased cardiovascular events and 
progression to dialysis [25]. Ambulatory blood pressure monitoring is 
required to disclose the presence of these conditions. However, home 
BP monitoring may be more practical in management of these patients 
day-to-day and may improve therapeutic inertia [26]. 
Conclusion and Future Directions 
 
The current best evidence for BP control in CKD favors less aggressive BP 
targets for people with CKD without proteinuria than for those with 
proteinuria. At present, there are few data to support that a BP goal of 
less than 130/80 mmHg saves lives, saves kidneys or reduces 
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cardiovascular events. Need for more research in special populations is 
needed such as in the elderly, very elderly, those with nephrotic 
albuminuria, those with diabetic kidney disease, and those with 
advanced atherosclerotic cardiovascular disease.  
 
The ongoing Systolic Blood Pressure Intervention Trial (SPRINT) holds 
promise in resolving some of these questions [27]. This is a multicenter, 
randomized, controlled trial that compares two strategies for treating 
systolic blood pressure: one targets the standard target of <140 mm Hg, 
and the other targets a more intensive target of <120 mm Hg. The 
recruitment has specifically targeted three subgroups: participants with 
chronic kidney disease (estimated glomerular filtration rate <60 
mL/min/1.73 m2), participants with a history of cardiovascular disease, 
and participants 75 years of age or older. Of the 9361 people recruited 
2648 have CKD. It is hoped that this study will provide more guidance 
particularly for systolic BP management in CKD and other high-risk 
subjects.  
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Table: 1 
Randomized trials of BP targets in CKD 
 MDRD 
(1994) [4] 
REIN-2 
(2005) [6] 
AASK (2002) 
[12] 
 
N studied 840 338 1094  
BP Targets 
Low vs. 
usual 
MAP < 92 vs 
< 107  
MAP < 98 vs 
< 113 (Age > 
61 yr) 
<130/80 vs 
DBP < 90  
MAP < 92 vs 
MAP 102-
107 
 
Primary 
Outcome 
Rate of 
change of 
GFR 
ESRD Composite 
of 50% 
reduction in 
GFR, ESRD 
and death 
 
Follow up  2.2 yr 
(mean) 
19 mths 
(median) 
3 – 6.4 yr 
(range) 
 
Primary 
Result 
No 
difference 
between 
groups 
No 
difference 
No 
difference 
 
MDRD: 
AASK: 
REIN-2: 
MAP: Mean arterial pressure 
DBP: Diastolic blood pressure 
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Table 2: Meta analyses on effect of intensive BP control in CKD 
 Upadhyay et al 
(2011) [15] 
Lv et al 
(2012) [28] 
Lv et al 
(2013) [16] 
Number of 
studies 
8 studies from 3 
trials* 
between 2001-
2011 
 
 
15 studies 
between 1950-
2011 
 
11 studies; 
between 1950-
2011 
 
 
 
Number of 
participants 
2272 37348  
(CKD 2734 
subjects) 
9287 
BP targets 125/75-130/80 
vs 140/90 
Identified an 
average of 
7.5/4.5-mmHg 
BP difference 
between 
groups. 
Varying targets 
in various 
studies 
Outcome(s) Death, ESRD, 
cardiovascular 
events, change 
in kidney 
function, 
number of 
antihypertensive 
agents, and 
adverse events.  
Effect on 
vascular, renal 
and ocular 
outcomes 
Composite of 
doubling of 
serum 
creatinine and 
50% fall in GFR 
or ESRD 
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Primary result No added 
benefit of lower 
BP 
11% (CI 1-21%) 
reduction in 
cardiovascular 
events, 11% (CI 
3-18%) 
reduction in 
ESRD 
Intensive BP 
lowering 
reduced the 
composite 
outcome risk 
(hazard ratio 
[HR] 0.82, [CI] 
0.68–0.98) and 
end-stage 
kidney disease 
(HR 0.79, 95% 
CI 0.67– 0.93) 
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